Roche CT-388 Obesity Drug Posts 22.5% Weight Loss
Roche CT-388 Obesity Drug shows up to 22.5% placebo-adjusted weight loss at 48 weeks, as Roche moves into Phase 3 to challenge Lilly and Novo.
Trade Tariffs and Their Impact on Pharmaceuticals
Explore the impact of trade tariffs on the pharmaceutical industry with the new EU-US trade deal imposing up to 15% tariffs.
Immunotherapy for Cancer and Early-Stage Success
Explore immunotherapy for cancer and its transformative impact on treatment at earlier stages, improving survival rates.
Roche sues over alleged misuse of trade secrets
Roche sues Stanford University and Foresight Diagnostics, alleging misuse of genetic-sequencing trade secrets to develop competing cancer-detection products.